卡塔尔波尔通过减弱粉样β斑块和神经炎症来拯救认知缺陷
Si Li1, Ziqi Tian2, Xiaohui Xian3
1Department of Technology, Hebei University of Chinese Medicine, Shijiazhuang, China.
概括
在阿尔茨海默病 (AD) 鼠标模型中,Catalpol有效降低了粉样蛋白-β (Aβ) 沉积和神经炎症. 这种天然化合物保护神经元并改善认知功能,表明其作为AD治疗的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β (Aβ) 斑块和神经炎症.
- 目前针对阿尔茨海默病的治疗方法的疗效有限.
- 识别新型治疗剂对于管理AD进展至关重要.
研究的目的:
- 为了研究catalpol.pol.的抗粉原和抗神经炎症作用.
- 在已建立的阿尔茨海默病小鼠模型中评估catalpol的疗效.
- 为了确定catalpol对认知功能和神经元保护的影响.
主要方法:
- 卡塔尔波尔对Aβ形成的影响使用黄素T检测法进行了评估.
- 细胞因子表达,微细胞毒性和Aβ水平通过qPCR,ELISA和氧化还原试验进行测量.
- 在APPswe/PS1ΔE9小鼠的认知功能使用水迷宫和新型物体识别测试进行了评估.
主要成果:
- 卡塔尔波尔显著抑制了Aβ纤维素和寡合体的形成.
- 卡塔波尔降低了促炎性细胞因子 (TNF-α,IL-6,iNOS) 和增加了微质中的抗炎性IL-10.
- 在AD小鼠中,用catalpol治疗降低了Aβ沉积,神经炎症和认知缺陷.
结论:
- 卡塔尔波尔显示出强大的抗粉原和抗神经炎症性质.
- 在AD小鼠模型中,Catalpol通过减轻Aβ沉积和神经炎症来保护神经元.
- 卡塔尔波尔 (Catalpol) 是阿尔茨海默病治疗的有前途的治疗候选药物.
更多相关视频
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
23.3K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.6K
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
165
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
165
Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223
Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
